Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Regeneron Pharmaceuticals    REGN

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets

Regeneron: Sanofi Plans to Increase Stake to Over $500 Million of Stock

share with twitter share with LinkedIn share with facebook
share via e-mail
0
02/11/2013 | 04:44pm CET
   By Melodie Warner 
 

Regeneron Pharmaceuticals Inc. (>> Regeneron Pharmaceuticals Inc) said Sanofi S.A. (SNY, SAN.FR) notified the biopharmaceutical company of its intent to boost its investment in the company and push its ownership of voting securities to more than $500 million.

Sanofi currently holds about 17% of Regeneron's shares outstanding, according to FactSet Research.

Regeneron said a December 2007 investor agreement bonds the French drug maker to certain standstill provisions, including an agreement not to acquire more than 30% of Regeneron's Class A stock and common stock outstanding.

Regeneron said these standstill provisions are in effect until the fifth anniversary of the expiration of a license and collaboration agreement between the companies.

Sanofi and Regeneron have worked together on experimental cancer drug Zaltrap, among other things.

Shares of Regeneron rose 5.6% to $175.13 in recent trading and have climbed 24% in the past three months.

Write to Melodie Warner at [email protected]

Subscribe to WSJ: http://online.wsj.com?mod=djnwires

Stocks mentioned in the article : Regeneron Pharmaceuticals Inc
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on REGENERON PHARMACEUTICALS
01/22 REGENERON PHARMACEUTICALS : Announces Approval of DUPIXENT® (dupilumab) in Japan..
01/19 REGENERON PHARMACEUTICALS : and Sanofi To Accelerate and Expand Investment for C..
01/18 REGENERON PHARMACEUTICALS INC : Change in Directors or Principal Officers (form ..
01/11 REGENERON PHARMACEUTICALS : forms consortium to accelerate largest widely-availa..
01/09 SANOFI : and Regeneron to accelerate and expand investment for cemiplimab and du..
01/08 SANOFI : and Regeneron boost investment in cancer drug cemiplimab
01/08 REGENERON PHARMACEUTICALS : and Sanofi To Accelerate and Expand Investment for C..
01/08 REGENERON PHARMACEUTICALS : Forms Consortium of Leading Life Sciences Companies ..
01/04 REGENERON PHARMACEUTICALS : Researchers Submit Patent Application, "Animal Model..
01/02 REGENERON PHARMACEUTICALS INC : Change in Directors or Principal Officers (form ..
More news
News from SeekingAlpha
08:00a YOUR DAILY PHARMA SCOOP : Omeros' OMS721, Celgene To Acquire Juno, BioCryst And ..
05:11a BULLETPROOF INVESTING PERFORMANCE : Week 8
01/22 Regeneron's Dupixent OK'd in Japan for atopic dermatitis
01/21 CLEMENTIA : A Game Changer In The Rare Disease Market Trading At Low Multiples T..
01/19 The Passive/Aggressive Portfolio
Financials ($)
Sales 2017 5 770 M
EBIT 2017 2 455 M
Net income 2017 1 485 M
Finance 2017 2 259 M
Yield 2017 -
P/E ratio 2017 29,43
P/E ratio 2018 26,92
EV / Sales 2017 6,61x
EV / Sales 2018 5,83x
Capitalization 40 382 M
Chart REGENERON PHARMACEUTICALS
Duration : Period :
Regeneron Pharmaceuticals Technical Analysis Chart | REGN | US75886F1075 | 4-Traders
Technical analysis trends REGENERON PHARMACEUTICALS
Short TermMid-TermLong Term
TrendsBearishBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 27
Average target price 447 $
Spread / Average Target 19%
EPS Revisions
Managers
NameTitle
Leonard S. Schleifer President, Chief Executive Officer & Director
P. Roy Vagelos Chairman
Robert E. Landry Chief Financial Officer & Senior VP-Finance
George Damis Yancopoulos Director & Chief Scientific Officer
Charles A. Baker Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
REGENERON PHARMACEUTICALS-1.18%40 382
GILEAD SCIENCES13.04%106 315
VERTEX PHARMACEUTICALS5.41%40 948
GENMAB13.75%11 797
BIOVERATIV INC18.90%11 230
JUNO THERAPEUTICS INC48.35%9 819